News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

“Do It Yourself” Dermatopathology Will Use Consumer’s Cell Phone Images

Company intends to use pattern recognition software to evaluate risk of skin cancer

A “do it yourself” dermatopathology service for consumers is coming soon, according to Health Discovery Corporation (HDC) of Savannah, Georgia. The company is preparing to introduce a cell phone-based tool to help consumers recognize whether a mole or other skin lesion needs examination by a dermatologist.

Using their cell phone cameras, consumers would click a photo of the skin lesion, then forward that image to a computer at HDC. Using pattern recognition algorithms developed by the company, called Support Vector Machines, the computer would analyze the image. A report telling the consumer whether the lesion was low, medium or high risk for skin cancer would be sent as a text message. This text message would include a list of dermatologists located near the consumer. The list of dermatologist referrals would be targeted to the user’s geographic area. HPC would compile this list, based on GPS data collected from the cell phone transmission.

(more…)

FISH-Based Test to Diagnose Melanoma is Goal of Neogenomics

Deal with Abbott Labs gives Neogenomics access to proprietary probes

Diagnostic testing for melanoma generates a substantial number of tests annually, making it a lucrative target for any clinical laboratory or biotech company that can develop an assay that utilizes state-of-the-art molecular technologies and offers improved detection and accuracy.

Once company working to develop such a new diagnostic test for melanoma is Neogenomics, Inc. (OTC:NGNM.OB).  It announced an agreement with Abbott Laboratories, Inc. (NYSE:ABT). on July 24, 2009. Abbott Laboratories will supply Neogenomics with proprietary probes to develop and commercialize its own FISH-based (Fluorescence in situ hyrbridization) test for melanoma.

(more…)

;